QIAGEN Beats Forecasts, Fortifies Market Position with Key Acquisitions

VENLO, Netherlands – February 04, 2026 – QIAGEN N.V. has reported robust financial results for the fourth quarter and full-year 2025, surpassing its own guidance and demonstrating significant resilience in a complex global economic environment. The life sciences and molecular diagnostics leader attributed its strong performance to disciplined execution and vigorous growth in its key strategic business areas, even while navigating macroeconomic pressures and the operational impacts of a U.S. government shutdown in 2025.

For the fourth quarter, the company announced net sales rose 4% to $540 million. At constant exchange rates (CER), this represented a 1% increase, outperforming the company's outlook which had projected steady CER results. This growth was achieved despite an approximate $10 million headwind from the discontinuation of its NeuMoDx and Dialunox product lines. Adjusted diluted earnings per share (EPS) for the quarter stood at $0.62 CER, comfortably beating the anticipated $0.60 CER.

Looking at the full-year performance, QIAGEN achieved 5% CER net sales growth, landing at the high end of its revised outlook. The company's full-year adjusted diluted EPS reached $2.40 CER, ahead of its $2.38 CER forecast and a full $0.12 above the initial guidance for 2025. This solid performance underscores the company's ability to effectively manage its portfolio and operations in a challenging climate.

“QIAGEN finished 2025 with disciplined execution, exceeding our outlook for sales and adjusted EPS in Q4 2025,” said Thierry Bernard, CEO of QIAGEN. “Our performance underscores the strength of our portfolio and positions us well to demonstrate our commitment to delivering solid profitable growth in a challenging environment.”

The Engine Room: Deconstructing QIAGEN's Growth Pillars

The driving force behind the company's success is its designated 'growth pillars,' a portfolio of high-demand products and platforms that collectively delivered 8% CER growth for the full year, accounting for $1.49 billion in combined sales. These pillars represent the company's strategic focus on the most dynamic segments of the molecular testing and life sciences markets.

Key components of this growth engine include:

• QIAstat-Dx: This platform for syndromic testing has been a standout performer, consistently showing strong double-digit growth throughout 2025. Its success is fueled by a growing installed base of instruments in hospitals and labs, coupled with an expanding menu of tests that can quickly identify the cause of various infectious diseases.

• QuantiFERON: The company's flagship blood test for latent tuberculosis continues to capture market share from traditional skin tests. Robust demand, particularly in the Americas and Europe, has cemented its position as a significant and reliable revenue driver.

• QIAcuity: QIAGEN's digital PCR system is gaining significant traction. The platform's precision is highly valued in research and diagnostics, and the company has seen healthy demand for its associated consumables while securing strategic deals for companion diagnostic development.

• QIAGEN Digital Insights (QDI): The bioinformatics arm of the company continues to expand its contribution, providing the critical data analysis and interpretation tools that complete the 'Sample to Insight' workflow for customers in genomics research and clinical settings.

For 2026, QIAGEN projects these growth pillars will accelerate further, forecasting about 9% CER growth and combined sales of approximately $1.64 billion.

Strategic Acquisitions Fortify Future Growth

Beyond strong organic growth, QIAGEN sharpened its competitive edge in 2025 with two strategic 'bolt-on' acquisitions, positioning the company for leadership in next-generation markets. These moves highlight a disciplined capital allocation strategy that balances immediate shareholder returns with long-term investment in innovation.

In December 2025, QIAGEN completed the acquisition of Parse Biosciences, marking a significant entry into the rapidly expanding field of single-cell analysis. This technology, which allows researchers to study biological processes at the individual cell level, is crucial for advancements in oncology, immunology, and neuroscience. The acquisition expands QIAGEN's core Sample technologies portfolio and began contributing to net sales in the fourth quarter.

The company also acquired Genoox, a specialist in genomics data interpretation. This move directly strengthens the QIAGEN Digital Insights (QDI) business by enhancing its ability to help researchers and clinicians make sense of complex genomic data, turning raw information into actionable clinical insights. This acquisition reinforces QIAGEN's end-to-end solution capabilities.

“We also made good progress in capital allocation,” noted Roland Sackers, the company's CFO. He pointed to the dual strategy of investing in the business while rewarding investors, stating, “We returned more than $1.1 billion to shareholders to date ahead of schedule and closed two bolt-on acquisitions with Genoox strengthening our QDI business and Parse expanding our Sample technologies portfolio with our entry into single-cell analysis.”

A Confident Outlook and Path to 2028

Building on the momentum of 2025, QIAGEN has issued a confident outlook for 2026. The company expects net sales growth of at least 5% CER and adjusted diluted EPS of at least $2.50 CER. This forecast signals management's belief in the continued strength of its core business and the successful integration of its new acquisitions.

The company's leadership emphasized that this performance keeps it firmly on course to meet its ambitious long-term strategic goals for 2028. A key part of this long-term strategy is a focus on operational efficiency and profitability. CEO Thierry Bernard confirmed the company continues to “drive efficiency and digitization across the organization to fund growth investments and expand profitability.”

Indeed, internal progress on this front appears to be ahead of schedule. The company is reportedly progressing faster than planned toward its mid-term goal of achieving an adjusted operating income margin of at least 31% by 2028. This combination of top-line growth, strategic investment in high-potential markets, and a disciplined approach to profitability provides a clear roadmap for the company's trajectory in the coming years.